What are the treatment and prevention strategies for brushite kidney stones?

Treatment and Prevention of Brushite Kidney Stones

Brushite stone formers require aggressive metabolic evaluation and treatment because they have exceptionally high recurrence rates (38-84%), large stone burdens, and nearly universal metabolic abnormalities—most critically hypercalciuria (81-85%), elevated urinary pH (>6.2 in 62%), and hyperphosphaturia (43%).1, 2

Initial Evaluation and Stone Analysis

• Obtain stone composition analysis at least once to confirm brushite content, as 62% of brushite stones are mixed with calcium oxalate and/or carbonate apatite, which affects treatment strategy.3, 1
• Perform two 24-hour urine collections on a random diet, measuring volume, pH, calcium, oxalate, uric acid, citrate, sodium, potassium, creatinine, and phosphate—all brushite formers will have at least one abnormality.3, 1
• Measure serum intact parathyroid hormone if serum calcium is high or high-normal to exclude primary hyperparathyroidism.3
• Screen for distal renal tubular acidosis (dRTA) with an ammonium chloride loading test, as 50% of brushite formers have dRTA, which causes persistently elevated urinary pH and impaired urine acidification.1
• Review imaging to quantify stone burden, as 34% of brushite formers present with bilateral stones.3, 2

Critical Pitfall

Nearly 80% of brushite formers have prior shock wave lithotripsy (SWL) exposure, and some evidence suggests SWL may cause nephron injury leading to failure of urine acidification and transformation from calcium oxalate to brushite stone disease.4, 2 This history should raise suspicion for iatrogenic brushite formation.

Dietary Management (First-Line Therapy)

Dietary intervention significantly reduces brushite supersaturation and should be the foundation of treatment.1

Fluid Intake

• Prescribe fluid intake to achieve at least 2.5 liters of urine output daily—this is the single most powerful preventive measure.3, 5
• For brushite formers, target closer to 3 liters daily given their high recurrence risk.5

Sodium Restriction

• Limit sodium to 2,300 mg (100 mEq) daily maximum, as sodium increases urinary calcium and phosphate excretion, both critical drivers of brushite formation.3, 5, 1

Calcium Intake

• Maintain normal dietary calcium at 1,000-1,200 mg daily from food sources—never restrict calcium, as this paradoxically increases urinary oxalate and stone risk.3, 5
• Avoid calcium supplements unless medically necessary, as they increase stone risk by 20% compared to dietary sources.5

Protein Restriction

• Reduce non-dairy animal protein to 5-7 servings of meat, fish, or poultry per week, as animal protein increases urinary calcium, phosphate, and uric acid while decreasing citrate.5, 1

Phosphate Considerations

• While not explicitly addressed in guidelines, the 43% prevalence of hyperphosphaturia in brushite formers suggests limiting high-phosphate foods (processed foods, colas, dairy in excess) may be beneficial.1

Pharmacological Management

Urinary Acidification (Cornerstone of Brushite Prevention)

The most critical intervention for brushite stones is lowering urinary pH below 6.2 to prevent brushite and carbonate apatite crystallization.6

• Do NOT use potassium citrate in brushite formers—this is the opposite of calcium oxalate management. Citrate alkalinizes urine and will worsen brushite formation.6
• Use urinary acidification with L-methionine to maintain urine pH <6.2, which prevents crystallization of brushite, carbonate apatite, and struvite.6
• Monitor urine pH regularly and adjust acidification therapy to maintain target pH 5.8-6.2.6

Thiazide Diuretics for Hypercalciuria

• Prescribe thiazide diuretics (hydrochlorothiazide 25-50 mg daily or chlorthalidone 25 mg daily) for the 81-85% of brushite formers with hypercalciuria (>250 mg/day in women, >300 mg/day in men).5, 1, 2
• Thiazides reduce urinary calcium excretion and stone recurrence (relative risk 0.52).5
• Continue strict sodium restriction to maximize the hypocalciuric effect of thiazides.3
• Monitor serum potassium for hypokalemia and fasting glucose for metabolic effects.5

Management of Distal RTA

• For the 50% of brushite formers with dRTA, acidification therapy with L-methionine is essential to compensate for the kidney's inability to acidify urine.1, 6
• These patients may require higher doses of acidifying agents and more frequent pH monitoring.6

Allopurinol for Hyperuricosuria

• Use allopurinol 200-300 mg daily if urinary uric acid exceeds 800 mg/day and urinary calcium is normal.3, 5
• Monitor liver enzymes periodically.5

Surgical Management

Brushite stones are notoriously resistant to extracorporeal shock wave lithotripsy (ESWL), with stone-free rates of only 11% with ESWL monotherapy.7

• Percutaneous nephrolithotomy (PCNL) is the preferred surgical approach for brushite stones, achieving 92% stone-free rates.7, 2
• Ureteroscopy with laser lithotripsy is appropriate for smaller stones or ureteral stones, with 92% success when combined with appropriate techniques.7
• Avoid ESWL as primary therapy for brushite stones due to their hardness and resistance to fragmentation—ballistic fragmentation is typically required.4, 7
• Obtain perioperative antibiotic prophylaxis for all endourological procedures.3

Surgical Pitfall

Given the 78% rate of prior SWL exposure in brushite formers and evidence that SWL may contribute to brushite transformation, minimize repeat SWL treatments in these patients.4, 2

Monitoring and Follow-Up

• Obtain 24-hour urine collection within 6 months of starting dietary and pharmacological therapy to assess response.3, 5
• Repeat 24-hour urine annually or more frequently given the 38% recurrence rate at mean 33 months.5, 2
• Monitor serum potassium if using thiazides (risk of hypokalemia).5
• Check liver enzymes if using allopurinol.5
• Verify urine pH regularly (ideally patient self-monitoring) to ensure acidification therapy maintains pH <6.2.6
• Repeat stone analysis if recurrence occurs, as stone composition may change.5

Special Considerations

Genetic Testing

• Consider genetic testing in brushite formers, as 80% have genetic variants and 67% have variants associated with hypophosphatemic rickets.8
• Two or more variants are present in 40% of brushite formers, suggesting intrinsic kidney abnormalities.8

Infection Stone Component

• If struvite is present (infection stone), add antibiotic therapy and consider chemolysis with acidification using Suby G solution or hemicidrin.6
• Urinary acidification with L-methionine supports infection treatment while preventing brushite crystallization.6

Key Differences from Calcium Oxalate Management

Brushite management fundamentally differs from calcium oxalate stones:

• Acidify urine (pH <6.2) rather than alkalinize—potassium citrate is contraindicated.6
• Expect higher recurrence rates (38% vs. typical calcium oxalate rates) requiring more aggressive follow-up.2
• Avoid ESWL due to stone hardness—choose PCNL or ureteroscopy.4, 7
• Screen for dRTA (50% prevalence in brushite vs. rare in calcium oxalate).1
• Monitor phosphate excretion in addition to standard parameters.1